Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis.

ABSTRACT:

Introduction/aim

Long-term efficacy and safety of dichlorphenamide (DCP) were characterized in patients with primary periodic paralysis (PPP).

Methods

Patients with PPP in a double-blind, placebo-controlled study were randomly assigned to receive DCP 50 mg twice daily or placebo for 9 weeks, followed by a 52-week open-label DCP treatment phase (DCP/DCP and placebo/DCP populations). Efficacy (attack rate, severity-weighted attack rate) and safety were assessed in patients completing the study (61 weeks). In this post hoc analysis, efficacy and safety data were pooled from hyperkalemic and hypokalemic substudies.

Results

Sixty-three adults (age, 19-76 years) completed the double-blind phase; 47 (74.6%) of these patients completed 61 weeks. There were median decreases in

SUBMITTER: Sansone VA 

PROVIDER: S-EPMC9290603 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature